Robert Gadimian, who possesses 20 years of hands-on experience in the pharmaceutical industry, provides client-centered solutions at the helm of Perceptive Regulatory Consulting. Also guiding Rophe Pharma, Robert Gadimian has overseen development of a variety of novel, patent pending compounds, including a formulation focused on hair and eyebrow growth.
The RPHE-7193 topical hair growth compound targets common male pattern baldness (MPB), or androgenetic alopecia, which is responsible for approximately 95 percent of men’s hair loss. With 85 percent of men experiencing significantly thinning hair by age 50, the unwanted process of MPB can even start before the age of 21.
Rophe Pharma has already obtained data related to the use of RPHE-7193 that indicates its promise in encouraging topical hair growth. With these initial results suggesting that the compound may have greater effectiveness than minoxidil, the next step is to launch controlled clinical studies.
A core focus will be on better understanding the distinction between minoxidil’s mechanism of stimulating hair growth, as a direct potassium channel blocker, and RPHE-7193’s reliance on calcium-activated potassium channels. The latter approach is one that encourages Ca2+ influx and promotes membrane depolarization, in ways that have a similar hair growth effect as minoxidil.